Nader Eldika, MD
Pulmonary Disease · Wichita, KSNPI 1033231006
Payments from drug & device makers
Across 439 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$964
- Boehringer Ingelheim$824
- Sanofi$361
- Genentech USA, Inc.$349
- plus $3K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 99 | $2,034 |
| AstraZeneca | 83 | $1,808 |
| Actelion Pharmaceuticals US, Inc. | 47 | $964 |
| Boehringer Ingelheim | 28 | $824 |
| Sanofi | 15 | $361 |
| Genentech USA, Inc. | 21 | $349 |
| Regeneron Healthcare Solutions, Inc. | 13 | $348 |
| United Therapeutics Corporation | 14 | $315 |
| Axsome Therapeutics, Inc. | 10 | $217 |
| Grifols USA, LLC | 7 | $174 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $161 |
| Novartis | 9 | $155 |
| Sunovion Pharmaceuticals Inc. | 23 | $142 |
| Mylan Specialty L.p. | 7 | $142 |
| AbbVie | 4 | $133 |
| Johnson & Johnson(2 entities) | 8 | $125 |
| Jazz Pharmaceuticals Inc. | 5 | $123 |
| Amgen | 6 | $105 |
| Advanced Respiratory, Inc | 4 | $86 |
| Sanofi-aventis U.S. LLC | 2 | $75 |
| Viatris Specialty LLC | 3 | $72 |
| Bayer | 3 | $63 |
| Baxter Healthcare | 3 | $55 |
| Verona Pharma, Inc. | 2 | $42 |
| Merck | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Insmed, Inc. | 2 | $33 |
| La Jolla Pharmaceutical Company | 2 | $30 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Resmed Corp | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Electromed, Inc. | 2 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Pfizer | 1 | $15 |
| Circassia Inc. | 1 | $14 |
How this compares
$9,163 in reported general payments places this provider in the 70th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Wichita
- Abdel-Ghanie Abu-SamraWichita$60K
- Youssef YammineWichita$19K
- Victor SalloumWichita$14K
- Ibrahim RaphaelWichita$13K
- Dennis Oyieng'oWichita$9K
- Mark WencelWichita$9K
- John FlesherWichita$7K
- Raid Abu-AwwadWichita$6K
- Maged El-ZeinWichita$4K
- Son TruongWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.